These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions
Front Neurosci 15: 781964
Our commitment to a collaborative and supportive environment means that we work closely with each patient to develop a sustainable, long-term weight management plan
For this reason, its important to work with a trusted, licensed medical professional to ensure youre receiving medication that is high-quality and effective
Improved overall sense of well-being